Health Affairs February 3, 2023
Jalpa A. Doshi, Amy Niles

The Inflation Reduction Act (IRA) of 2022 marks the first major overhaul of the Medicare Part D prescription drug benefit in over a decade. Media coverage has largely focused on one Medicare reform enacted through the IRA—a $2,000 limit on annual Part D out-of-pocket prescription costs starting in 2025. However, an equally important provision in the legislation has been overlooked: giving beneficiaries the option of “smoothing” their Part D out-of-pocket costs starting in 2025. In contrast to the current Part D benefit structure where out-of-pocket costs are typically frontloaded at the start of each calendar year, the “smoothing” option will allow Medicare beneficiaries to spread their out-of-pocket prescription costs more evenly with monthly installments. Smoothing has the potential to be...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech
HHS Announces Medicaid and Medicare Flexibilities, Investigations post-Change Healthcare Cyberattack
Medicare, Medicaid made $100B in improper payments in 2023
Medicare’s GLP-1 spending is skyrocketing, even without weight loss coverage: KFF
Can Hospital At Home Finally Hit Its Tipping Point? Lessons From The Hospitalist Field
Is Medicare keeping pace with our aging population? Experts say 'we need to double down and go faster'

Share This Article